Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques.
- 0
Anti-cancer immunotherapy is rising from a nadir and demonstrating tangible advantages to sufferers. A wide range of approaches are actually employed. We’re invoking antigen (Ag)-specific responses via direct injections of recombinant lentivectors (LVs) that encode sequences for tumor-associated antigens into a number of lymph nodes to optimize immune presentation/stimulation.
Right here we first exhibit the effectiveness and antigen-specificity of this strategy in mice challenged with prostate-specific antigen (PSA)-expressing tumor cells. Subsequent we examined the protection and efficacy of this strategy in two cohorts of rhesus macaques as a prelude to a medical trial utility.
Our vector encodes the cDNA for rhesus macaque PSA and a rhesus macaque cell floor marker to facilitate vector titering and monitoring. We utilized two unbiased injection schemas demarcated by the timing of LV administration. In each cohorts we noticed marked tissue-specific responses as measured by medical evaluations and magnetic resonance imaging of the prostate gland.
Tissue-specific responses had been sustained for as much as six months-the end-point of the research. Management animals immunized towards an irrelevant Ag had been unaffected. We didn’t observe vector unfold in take a look at or management animals or perturbations of systemic immune parameters. This strategy thus gives an “off-the-shelf” anti-cancer vaccine that could possibly be made at giant scale and injected into patients-even on an out-patient foundation.
Intratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Technique for Enhancing the Antitumor Impact of Remedy Composed of Cyclophosphamide and Dendritic Cells.
Vaccination with dendritic cells (DCs) stimulated with tumor antigens can induce particular mobile immune response that acknowledges a excessive spectrum of tumor antigens. Nevertheless, the flexibility of most cancers cells to provide immunosuppressive components drastically decreases the antitumor exercise of DCs.
The principle objective of the research was to enhance the effectiveness of DC-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by utility of lentivectors (LVs)-encoding brief hairpin RNA particular for TGF-β1 (shTGFβ1 LVs). We noticed that s.c. inoculation of each MC38 cells with silenced expression of TGF-β1 (MC38/shTGF-β1) and direct intratumoral utility of shTGFβ1 LVs contributed to discount of suppressor exercise of myeloid cells and Tregs in tumor.
Opposite to expectations, in mice bearing wild tumor, the applying of shTGFβ1 LVs previous to vaccination with bone marrow-derived DC stimulated with tumor antigens (BMDC/TAg) didn’t affect myeloid-derived suppressor cell (MDSC) infiltration into tumor. Because of this, we noticed solely minor MC38 tumor development inhibition (TGI) accompanied by systemic antitumor response activation similar to that obtained for destructive management (shN).
Nevertheless, when the proposed scheme was complemented by pretreatment with a low dose of CY, we seen excessive MC38 TGI along with decreased variety of MDSCs in tumor and induction of Th1-type response. Furthermore, in each schemes of remedy, LVs (shTGFβ1 in addition to shN) induced excessive inflow of CTLs into tumor related in all probability with the viral antigen introduction into tumor microenvironment. Concluding, the applying of shTGFβ1 LVs alone or together with DC-based vaccines just isn’t adequate for long-lasting elimination of suppression in tumor.
Nevertheless, simultaneous discount of TGF-β1 in tumor microenvironment and its transforming by pretreatment with a low dose of CY facilitates the settlement of peritumorally inoculated DCs and helps them in restoration and activation of a potent antitumor response.
Dendritic Cells Cross-Current Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Purposeful T Cell Immunity.
Recombinant lentiviral vectors (LVs) are extremely efficient vaccination autos that elicit protecting T cell immunity in illness fashions. Dendritic cells (DCs) purchase antigen at websites of vaccination and migrate to draining lymph nodes, the place they prime vaccine-specific T cells. The efficiency with which LVs activate CD8+ T cell immunity has been attributed to the transduction of DCs on the immunization website and sturdy presentation of LV-encoded antigens.
Nevertheless, it’s not recognized how LV-encoded antigens proceed to be offered to T cells as soon as straight transduced DCs have turned over. Right here, we report that LV-encoded antigen is effectively cross-presented by DCs in vitro. We have now additional exploited the temporal depletion of DCs within the murine CD11c.DTR (diphtheria toxin receptor) mannequin to exhibit that repopulating DCs that had been absent on the time of immunization cross-present LV-encoded antigen to T cells in vivo.
Oblique presentation of antigen from transduced cells by DCs is adequate to prime practical effector T cells that management tumor development. These information recommend that DCs cross-present immunogenic antigen from LV-transduced cells, thereby facilitating extended activation of T cells within the absence of circulating LV particles. These are findings which will affect on the longer term design of LV vaccination methods.
Optimization of a Genome-Broad Disordered Lentivector-Primarily based Brief Hairpin RNA Library.
To acquire an entire genome library that suppresses the full variety of human mRNAs, lentiviral vector constructs and a brief hairpin RNA (shRNA) expression cassette had been optimized. The optimization of the vector elevated the virus titer in preparations by 15-20 instances. A easy shRNA construction with a 21-bp stem proved to be the simplest.
Lentivector-based shRNA expression constructs had been obtained through the use of puro(R), copGFP, or H-2K(okay) as a selectable marker. The effectivity of the optimized library was demonstrated when screening for shRNAs reactivating the tumor suppressor p53 in HeLa cells. Cells carried a reporter assemble guaranteeing p53-responsive synthesis of a fluorescent protein, which allowed choice of cells with reactivated p53 by stream cytometry.
Injectable alginate hydrogel for enhanced spatiotemporal management of lentivector supply in murine skeletal muscle.
Hydrogels are an particularly interesting class of biomaterials for gene supply autos as they are often launched into the physique with minimally invasive procedures and are sometimes utilized in tissue engineering and regenerative medication methods. On this research, we present for the primary time using an injectable alginate hydrogel for managed supply of lentivectors within the skeletal muscle of murine hindlimb. We suggest to change the discharge charges of lentivectors via manipulation of the molecular weight distribution of alginate hydrogels.
The discharge of lentivector was examined utilizing two completely different ratios of high and low molecular weight (MW) alginate polymers (75/25 and 25/75 low/excessive MW). The interdependency of lentivector launch fee and alginate degradation fee was assessed in vitro. Lentivector-loaded hydrogels maintained transduction potential for as much as one week in vitro as demonstrated by the continuous transduction of HEK-293T cells.
CENPQ Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV662123 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV662647 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV662651 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV664129 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPT Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV664133 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV669043 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV669047 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV669049 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV669053 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV700843 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPW Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV700847 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV661477 | ABM | 1.0 ug DNA | EUR 1626 |
CENPI Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV661481 | ABM | 1.0 ug DNA | EUR 1626 |
Cenpk ORF Vector (Mouse) (pORF) |
|||
| ORF041164 | ABM | 1.0 ug DNA | EUR 607.2 |
Cenpk ORF Vector (Mouse) (pORF) |
|||
| ORF041165 | ABM | 1.0 ug DNA | EUR 607.2 |
CENPK ORF Vector (Human) (pORF) |
|||
| ORF002253 | ABM | 1.0 ug DNA | EUR 114 |
CENPC1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV628759 | ABM | 1.0 ug DNA | EUR 1626 |
CENPC1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV628763 | ABM | 1.0 ug DNA | EUR 1626 |
CENPQ Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV662124 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPN Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV662652 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPT Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV664134 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV669048 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV669054 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV791311 | ABM | 1.0 ug DNA | EUR 379.2 |
CENPJ Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV702087 | ABM | 1.0 ug DNA | EUR 540 |
CENPJ Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702091 | ABM | 1.0 ug DNA | EUR 540 |
CENPA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV708615 | ABM | 1.0 ug DNA | EUR 379.2 |
CENPA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708619 | ABM | 1.0 ug DNA | EUR 379.2 |
CENPW Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV700848 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPI Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV661482 | ABM | 1.0 ug DNA | EUR 1626 |
CENPC1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV628764 | ABM | 1.0 ug DNA | EUR 1626 |
CENPO Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV791312 | ABM | 1.0 ug DNA | EUR 379.2 |
CENPIP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720971 | ABM | 1.0 ug DNA | Ask for price |
CENPIP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720975 | ABM | 1.0 ug DNA | Ask for price |
CENPJ Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV702092 | ABM | 1.0 ug DNA | EUR 540 |
CENPA Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV708620 | ABM | 1.0 ug DNA | EUR 379.2 |
Cenpk sgRNA CRISPR Lentivector set (Rat) |
|||
| K6564001 | ABM | 3 x 1.0 ug | EUR 406.8 |
CENPK |
|||
| CSB-CL005214HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
CENPC1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758915 | ABM | 1.0 ug DNA | Ask for price |
CENPC1P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758919 | ABM | 1.0 ug DNA | Ask for price |
CENPIP1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV720976 | ABM | 1.0 ug DNA | Ask for price |
CENPK sgRNA CRISPR Lentivector set (Human) |
|||
| K0432501 | ABM | 3 x 1.0 ug | EUR 406.8 |
Cenpk sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3101501 | ABM | 3 x 1.0 ug | EUR 406.8 |
CENPC1P1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV758920 | ABM | 1.0 ug DNA | Ask for price |
CENPQ Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV662120 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV662648 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV664130 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV669044 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV669050 | ABM | 1.0 ug DNA | EUR 818.4 |
CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV700844 | ABM | 1.0 ug DNA | EUR 616.8 |
CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV661478 | ABM | 1.0 ug DNA | EUR 1626 |
CENPC1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV628760 | ABM | 1.0 ug DNA | EUR 1626 |
Lenti ORF particles, CENPK (mGFP-tagged) - Human centromere protein K (CENPK), 200ul, >10^7 TU/mL |
|||
| RC203350L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Cenpk sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6564002 | ABM | 1.0 ug DNA | EUR 184.8 |
Cenpk sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6564003 | ABM | 1.0 ug DNA | EUR 184.8 |
Cenpk sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6564004 | ABM | 1.0 ug DNA | EUR 184.8 |
CENPQ Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV662121 | ABM | 1.0 ug DNA | EUR 686.4 |
CENPQ Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV662122 | ABM | 1.0 ug DNA | EUR 686.4 |
CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV662649 | ABM | 1.0 ug DNA | EUR 888 |
CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV662650 | ABM | 1.0 ug DNA | EUR 888 |
CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV664131 | ABM | 1.0 ug DNA | EUR 888 |
CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV664132 | ABM | 1.0 ug DNA | EUR 888 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV669045 | ABM | 1.0 ug DNA | EUR 888 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV669046 | ABM | 1.0 ug DNA | EUR 888 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV669051 | ABM | 1.0 ug DNA | EUR 888 |
CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV669052 | ABM | 1.0 ug DNA | EUR 888 |
CENPJ Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV702088 | ABM | 1.0 ug DNA | EUR 540 |
CENPA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV708616 | ABM | 1.0 ug DNA | EUR 379.2 |
CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV700845 | ABM | 1.0 ug DNA | EUR 686.4 |
CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV700846 | ABM | 1.0 ug DNA | EUR 686.4 |
CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV661479 | ABM | 1.0 ug DNA | EUR 1695.6 |
CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV661480 | ABM | 1.0 ug DNA | EUR 1695.6 |
Lenti ORF clone of Cenpk (mGFP-tagged ORF) - Rat centromere protein K (Cenpk), (10 ug) |
|||
| RR204447L4 | Origene Technologies GmbH | 10 µg | Ask for price |
CENPC1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV628761 | ABM | 1.0 ug DNA | EUR 1695.6 |
CENPC1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV628762 | ABM | 1.0 ug DNA | EUR 1695.6 |
CENPK sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0432502 | ABM | 1.0 ug DNA | EUR 184.8 |
CENPK sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0432503 | ABM | 1.0 ug DNA | EUR 184.8 |
CENPK sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0432504 | ABM | 1.0 ug DNA | EUR 184.8 |
Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3101502 | ABM | 1.0 ug DNA | EUR 184.8 |
Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3101503 | ABM | 1.0 ug DNA | EUR 184.8 |
Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3101504 | ABM | 1.0 ug DNA | EUR 184.8 |
Lenti ORF particles, Cenpk (GFP-tagged ORF) - Rat centromere protein K (Cenpk), 200ul, >10^7 TU/mL |
|||
| RR204447L4V | Origene Technologies GmbH | 200 µl | Ask for price |
CENPO Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV791310 | ABM | 1.0 ug DNA | EUR 448.8 |
CENPIP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV720972 | ABM | 1.0 ug DNA | Ask for price |
CENPJ Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV702089 | ABM | 1.0 ug DNA | EUR 609.6 |
CENPJ Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV702090 | ABM | 1.0 ug DNA | EUR 609.6 |
CENPA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV708617 | ABM | 1.0 ug DNA | EUR 448.8 |
CENPA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV708618 | ABM | 1.0 ug DNA | EUR 448.8 |
Lenti ORF particles, CENPK (Myc-DDK tagged) - Human centromere protein K (CENPK), 200ul, >10^7 TU/mL |
|||
| RC203350L3V | Origene Technologies GmbH | 200 µl | Ask for price |
CENPC1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV758916 | ABM | 1.0 ug DNA | Ask for price |
CENPIP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV720973 | ABM | 1.0 ug DNA | Ask for price |
CENPIP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV720974 | ABM | 1.0 ug DNA | Ask for price |
CENPK Protein Vector (Rat) (pPM-C-HA) |
|||
| PV259396 | ABM | 500 ng | EUR 723.6 |
CENPK (untagged)-Human centromere protein K (CENPK) |
|||
| SC310583 | Origene Technologies GmbH | 10 µg | Ask for price |
CENPK (untagged)-Human centromere protein K (CENPK) |
|||
| SC320818 | Origene Technologies GmbH | 10 µg | Ask for price |
CENPK Protein Vector (Rat) (pPB-C-His) |
|||
| PV259394 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Rat) (pPB-N-His) |
|||
| PV259395 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Rat) (pPM-C-His) |
|||
| PV259397 | ABM | 500 ng | EUR 723.6 |
CENPC1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV758917 | ABM | 1.0 ug DNA | Ask for price |
CENPC1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV758918 | ABM | 1.0 ug DNA | Ask for price |
Lenti ORF clone of Cenpk (Myc-DDK-tagged ORF) - Rat centromere protein K (Cenpk), (10 ug) |
|||
| RR204447L3 | Origene Technologies GmbH | 10 µg | Ask for price |
CENPK Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV164656 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV164660 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Human) (pPM-C-HA) |
|||
| PV009011 | ABM | 500 ng | EUR 394.8 |
Cenpq - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL702334 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpt - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL702543 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpu - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL702989 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpl - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL703173 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpn - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL701039 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpa - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL705286 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpj - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL705833 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpm - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL708543 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpi - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL709564 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
CENPK Protein Vector (Mouse) (pPB-C-His) |
|||
| PV164654 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPB-N-His) |
|||
| PV164655 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPM-C-His) |
|||
| PV164657 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPB-C-His) |
|||
| PV164658 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPB-N-His) |
|||
| PV164659 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Mouse) (pPM-C-His) |
|||
| PV164661 | ABM | 500 ng | EUR 723.6 |
CENPK Protein Vector (Human) (pPB-C-His) |
|||
| PV009009 | ABM | 500 ng | EUR 394.8 |
CENPK Protein Vector (Human) (pPB-N-His) |
|||
| PV009010 | ABM | 500 ng | EUR 394.8 |
CENPK Protein Vector (Human) (pPM-C-His) |
|||
| PV009012 | ABM | 500 ng | EUR 394.8 |
Lenti ORF particles, Cenpk (Myc-DDK-tagged ORF) - Rat centromere protein K (Cenpk), 200ul, >10^7 TU/mL |
|||
| RR204447L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Cenpc1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL700529 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Lenti ORF clone of Cenpk (mGFP-tagged) - Mouse centromere protein K (Cenpk), transcript variant 1 |
|||
| MR218070L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Cenpk (mGFP-tagged) - Mouse centromere protein K (Cenpk), transcript variant 2 |
|||
| MR217832L4 | Origene Technologies GmbH | 10 µg | Ask for price |
CENPS - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL306643 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpu - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL509422 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpt - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL508317 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Cenpj - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL506600 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Injection of lentivector-loaded hydrogel in vivo led to a sustained stage of transgene expression for greater than two months whereas minimizing the copies of lentivirus genome inserted into the genome of murine skeletal muscle cells. This technique of spatiotemporal management of lentivector supply from alginate hydrogels might present a flexible instrument to mix gene remedy and biomaterials for functions in regenerative medication.
